Qube Research & Technologies (QRT) Portfolio holdings
Qube Research & Technologies (QRT) is a British investment firm that trades with computer-driven models and began life inside Credit Suisse. It started in late 2016 as the Qube Fund, run by the bank's asset management unit for model-based strategies, and used computer models to trade stocks. Credit Suisse planned to spin the fund off because rules such as the Volcker Rule restricted banks from trading with their own money, and at the start of 2018 its management team bought the unit and renamed it Qube Research & Technologies. It runs a mix of strategies across many regions, asset classes and time horizons, with research teams of engineers, physicists, mathematicians, data scientists and fundamental analysts.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Warner Bros
WBD
|
+$1.31B |
| 2 |
NVIDIA
NVDA
|
+$1.03B |
| 3 |
Meta Platforms (Facebook)
META
|
+$840M |
| 4 |
Shopify
SHOP
|
+$815M |
| 5 |
Caterpillar
CAT
|
+$639M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1B |
| 2 |
Chevron
CVX
|
+$834M |
| 3 |
Sandisk
SNDK
|
+$632M |
| 4 |
Intercontinental Exchange
ICE
|
+$490M |
| 5 |
ExxonMobil
XOM
|
+$467M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 20.18% |
| 2 | Technology | 19.85% |
| 3 | Financials | 12.83% |
| 4 | Industrials | 10.55% |
| 5 | Healthcare | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2326
iShares MSCI Intl Momentum Factor ETF
IMTM
$4.12B
| $1.98M | ﹤0.01% |
+37,584
| New | +$1.99M |
2026 Q3
0 quarters
|
|
2327
First Advantage
FA
$3.69B
| $1.97M | ﹤0.01% |
+110,932
| New | +$2.3M |
2026 Q3
0 quarters
|
|
2328
Village Farms International
VFF
$296M
| $1.97M | ﹤0.01% |
678,530
-276,562
| -29% | -$682K |
2025 Q4
3 quarters
|
|
2329
CALL
Deckers Outdoor
DECK
$11.6B
| $1.97M | ﹤0.01% |
25,200
-1,200
| -5% | -$111K |
2024 Q4
7 quarters
|
|
2330
Metallus
MTUS
$699M
| $1.97M | ﹤0.01% |
103,660
+70,706
| +215% | +$1.4M |
2026 Q2
1 quarter
|
|
2331
ProShares Bitcoin Strategy ETF
BITO
$1.29B
| $1.96M | ﹤0.01% |
+175,400
| New | +$1.68M |
2026 Q3
0 quarters
|
|
2332
Unisys
UIS
$208M
| $1.96M | ﹤0.01% |
849,577
+626,180
| +280% | +$1.85M |
2024 Q1
10 quarters
|
|
2333
Jade Biosciences
JBIO
$1.03B
| $1.96M | ﹤0.01% |
+139,534
| New | +$2.8M |
2026 Q3
0 quarters
|
|
2334
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.24B
| $1.95M | ﹤0.01% |
+65,896
| New | +$1.89M |
2026 Q3
0 quarters
|
|
2335
Magnachip Semiconductor
MX
$95.1M
| $1.95M | ﹤0.01% |
518,794
+136,411
| +36% | +$470K |
2026 Q2
1 quarter
|
|
2336
Old Republic International
ORI
$9.5B
| $1.95M | ﹤0.01% |
+52,200
| New | +$2.17M |
2026 Q3
0 quarters
|
|
2337
EyePoint Inc
EYPT
$34.8M
| $1.95M | ﹤0.01% |
595,452
+406,350
| +215% | +$3.57M |
2026 Q1
2 quarters
|
|
2338
Candel Therapeutics
CADL
$486M
| $1.94M | ﹤0.01% |
+185,617
| New | +$2.06M |
2026 Q3
0 quarters
|
|
|
2339
CALL
DELISTED
Warner Bros
WBD
| $1.93M | ﹤0.01% |
62,500
-35,300
| -36% | -$978K |
2024 Q2
9 quarters
|
|
2340
Foghorn Therapeutics
FHTX
$124M
| $1.93M | ﹤0.01% |
540,315
+337,019
| +166% | +$1.77M |
2025 Q4
3 quarters
|
|
2341
Eagle Materials
EXP
$5.5B
| $1.93M | ﹤0.01% |
+11,275
| New | +$2.25M |
2026 Q3
0 quarters
|
|
2342
MNTN Inc
MNTN
$382M
| $1.93M | ﹤0.01% |
189,473
+37,627
| +25% | +$419K |
2025 Q3
4 quarters
|
|
2343
Core Scientific Inc Tranche 2 Warrants
CORZZ
$1.11B
| $1.92M | ﹤0.01% |
118,931
| – | – |
2024 Q1
10 quarters
|
|
2344
Vista Energy
VIST
$6.17B
| $1.91M | ﹤0.01% |
29,184
-336,619
| -92% | -$23.1M |
2026 Q1
2 quarters
|
|
2345
Summit Midstream
SMC
$420M
| $1.9M | ﹤0.01% |
+62,723
| New | +$2.01M |
2026 Q3
0 quarters
|
|
2346
PUT
Nucor
NUE
$56.6B
| $1.89M | ﹤0.01% |
8,100
-4,800
| -37% | -$1.2M |
2023 Q3
12 quarters
|
|
2347
CALL
KKR & Co
KKR
$87.5B
| $1.89M | ﹤0.01% |
20,700
-23,600
| -53% | -$2.41M |
2024 Q3
8 quarters
|
|
2348
Astrana Health
ASTH
$1.58B
| $1.89M | ﹤0.01% |
+53,116
| New | +$2.09M |
2026 Q3
0 quarters
|
|
2349
Allogene Therapeutics
ALLO
$291M
| $1.89M | ﹤0.01% |
+1,178,377
| New | +$2.24M |
2026 Q3
0 quarters
|
|
2350
PUT
Charter Communications
CHTR
$15.8B
| $1.89M | ﹤0.01% |
17,000
+3,800
| +29% | +$529K |
2023 Q3
12 quarters
|
|
Similar funds
Qube Research & Technologies (QRT)'s Q3 2026 Portfolio in Review
As of Q3 2026, Qube Research & Technologies (QRT) held 4,268 positions worth $123B, up 14% from $108B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Qube Research & Technologies (QRT) deployed $13.6B of net new capital in Q3 2026, opening 862 new positions and adding to 1,394 existing holdings. Its largest new stake was Caterpillar: 753,166 shares worth $611M.
By sector, the portfolio is most concentrated in Miscellaneous at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1B trimmed.
- Qube Research & Technologies (QRT)'s largest Q3 2026 buy was Caterpillar: 753,166 shares worth $611M.
- Qube Research & Technologies (QRT) added most to Warner Bros in Q3 2026, an estimated $1.31B increase.
- Qube Research & Technologies (QRT)'s biggest Q3 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1B.
- Qube Research & Technologies (QRT) fully exited Intercontinental Exchange in Q3 2026, selling an estimated $490M.
- Qube Research & Technologies (QRT)'s ten largest holdings make up 10% of its $123B portfolio in Q3 2026.
- Qube Research & Technologies (QRT) opened 862 new positions and closed 641 in Q3 2026.
- Qube Research & Technologies (QRT)'s portfolio value rose 14% quarter-over-quarter to $123B.
Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.